基于P值法的乳腺癌前哨淋巴结超声诊断价值
回顾性纳入157例乳腺癌患者,均行常规超声与淋巴超声造影,以病理为金标准,比较US、LCEUS、US+LCEUS、P值法及P值法+LCEUS五种方法对前哨淋巴结转移的诊断效能。结果显示P值法+LCEUS敏感度最高(92.65%),各方法AUC为0.798~0.845,组间两两比较未见统计学差异。
要点
- P值法+LCEUS对前哨淋巴结转移敏感度最高,适合作为术前无创筛查手段。
- P值法+LCEUS阴性预测值达93.15%,可用于识别低风险患者以减少不必要活检。
- 单独常规超声或LCEUS敏感度不足,报告时应结合P值法综合判断。
核心结论
- 以病理为金标准,P值法+LCEUS诊断乳腺癌前哨淋巴结转移的敏感度最高,为92.65%。
- 五种方法诊断前哨淋巴结的AUC为0.798~0.845,两两比较均无统计学差异。
- 术前基于LCEUS和P值法判断前哨淋巴结状态有助于减少低风险患者不必要的SLN活检。
研究设计与样本
- 所有患者术前行常规超声(US)和淋巴超声造影(LCEUS),以术后病理为金标准。
- 比较US、LCEUS、US+LCEUS、P值法、P值法+LCEUS五种方法的诊断效能。
关键影像表现/征象
- 前哨淋巴结转移阳性68例(43.31%),包括宏转移和微转移;阴性89例(56.69%),包括无转移和孤立肿瘤细胞簇。
诊断标准与关键数值
- US诊断准确度80.25%,敏感度76.47%,特异度83.14%,阳性预测值77.61%,阴性预测值82.22%,AUC 0.798。
- LCEUS诊断准确度81.53%,敏感度77.94%,特异度86.52%,阳性预测值81.54%,阴性预测值83.70%,AUC 0.822。
- US+LCEUS诊断准确度79.62%,敏感度88.24%,特异度73.03%,阳性预测值71.43%,阴性预测值89.04%,AUC 0.806。
- P值法诊断准确度84.08%,敏感度85.39%,特异度82.35%,阳性预测值86.36%,阴性预测值81.16%,AUC 0.839。
- P值法+LCEUS诊断准确度83.44%,敏感度92.65%,特异度76.40%,阳性预测值75.00%,阴性预测值93.15%,AUC 0.845。
临床应用与阅片要点
- 报告前哨淋巴结超声所见时,可补充P值法量化评估,辅助临床判断转移风险。
- P值法+LCEUS阴性预测值高,对低风险患者可作为减少SLN活检的影像依据。
- 单独使用US或LCEUS敏感度偏低,避免仅凭单一方法排除前哨淋巴结转移。
局限性
- 回顾性单中心研究,样本量为157例,结论外推需谨慎。
- 五种方法AUC两两比较均无统计学差异,诊断效能提升幅度有限。
- LCEUS为有创增强检查,临床普适性和操作可重复性可能受限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: It is essential to determine the location and evaluate the status of the sentinel lymph node (SLN) in breast cancer patients before surgery. However, the diagnostic performance of the conventional ultrasound (US) examination and lymphatic contrast-enhanced US (LCEUS) was not satisfied. This study aimed to explore the US diagnostic value of the relative p value method for SLN in breast cancer, to provide reference for precise clinical diagnosis.
METHODS: A retrospective collection of 157 breast cancer patients who were admitted to the Affiliated Hospital of Nanjing University of Chinese Medicine from July 2018 to December 2022 was conducted. All patients underwent US and LCEUS examinations before surgery and confirmed by pathology. Because pathology was considered the gold standard, the diagnostic efficacies of US, LCEUS, US + LCEUS, the p value method and the p value method + LCEUS were analyzed.
RESULTS: Using pathology as the gold standard, there were 68 cases (43.31%) in the SLN metastasis-positive group including macro-metastasis and micro-metastasis, whereas the SLN metastasis-negative group included 89 cases (56.69%), including no metastasis and isolated tumor cell clusters. Among 157 SLNs of breast cancer patients, five methods (ie, US, LCEUS, US + LCEUS, p value and p value + LCEUS) in diagnosing SLNs achieved, respectively, an accuracy of 80.25%, 81.53%, 79.62%, 84.08% and 83.44%; sensitivity of 76.47%, 77.94%, 88.24%, 85.39% and 92.65%; specificity of 83.14%, 86.52%, 73.03%, 82.35% and 76.40%; positive predictive value (of 77.61%, 81.54%, 71.43%, 86.36% and 75.00%; and negative predictive value of 82.22%, 83.70%, 89.04%, 81.16% and 93.15%. Additionally, the sensitivity of the p value + LCEUS method showed statistically significant differences when compared with that of the US and the LCEUS method, respectively (p < 0.05). A statistically significant difference in negative predictive value was observed between the US and the p value + LCEUS method (p < 0.05). Receiver operating characteristic curves were plotted for the diagnostic sensitivity of five groups (i.e., US, LCEUS, US + LCEUS p value and p value + LCEUS) in diagnosing SLNs of the breast. The areas under the curve (AUC) were 0.798, 0.822, 0.806, 0.839 and 0.845, respectively. No statistically significant differences were found in the pairwise comparisons.
CONCLUSION: The method of predicting the metastasis status of SLN based on pre-operative LCEUS and the p value method can assist clinicians in assessing the risk of SLN metastasis before surgery. It is possible to decrease unnecessary SLN biopsies in low-risk patients and lower the incidence of complications.
引用
- Wu, Jiang, Dong, et al. Ultrasound Diagnosis of Sentinel Lymph Nodes in Breast Cancer Based on the P Value Method. Ultrasound Med Biol. 2026. PMID: 41565537. doi:10.1016/j.ultrasmedbio.2025.12.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。